Wait, we have a special offer for you! ✋

Get your exclusive discount now

Use FY25SAVE to get flat 20% off on the report No, I'd pay the full price

Terms & Conditions : This coupon is vaild exclusively for Global Market Reports 2025 and can be used Until March 31 , 2025 .

Global Neuroendocrine Carcinoma Market Report 2025

Neuroendocrine Carcinoma Global Market Report 2025 - By Type (Gastroenteropancreatic Neuroendocrine Tumors, Carcinoid Tumors, Pheochromocytoma, Medullary Thyroid Carcinoma), By Diagnostic Tools (Imaging, Biopsy, Serology), By Treatment (Chemotherapy, Radiotherapy, Surgery, Other Treatments), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Hospitals, Clinics, Oncology Centers, Ambulatory Surgery Centers) - Market Size, Trends, And Global Forecast 2025-2034

Neuroendocrine Carcinoma Global Market Report 2025

Report Price : $4490.00 | Pages : 175 | Published : March 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request a Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Neuroendocrine Carcinoma Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

What Is Covered Under Neuroendocrine Carcinoma Market

Neuroendocrine carcinoma (NEC) refers to a rare and aggressive type of cancer that originates in neuroendocrine cells, which have traits of both nerve cells and hormone-producing cells. They are used for identifying and treating tumors that can develop in various organs, including the lungs, pancreas, and gastrointestinal tract, often requiring a combination of surgery, chemotherapy, and targeted therapies.

The main types of neuroendocrine carcinoma are gastroenteropancreatic neuroendocrine tumors, carcinoid tumors, pheochromocytoma, and medullary thyroid carcinoma. Gastroenteropancreatic neuroendocrine tumors are rare malignancies originating from neuroendocrine cells in the gastrointestinal tract or pancreas. It includes various diagnostic tools such as imaging, biopsy, and serology, with several treatments including chemotherapy, radiotherapy, surgery, and others. It is distributed through various distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and used by several end users, including hospitals, clinics, oncology centers, and ambulatory surgery centers.

How Is The Neuroendocrine Carcinoma Market Segmented?

The neuroendocrine carcinoma market covered in this report is segmented –

1) By Type: Gastroenteropancreatic Neuroendocrine Tumors, Carcinoid Tumors, Pheochromocytoma, Medullary Thyroid Carcinoma

2) By Diagnostic Tools: Imaging, Biopsy, Serology

3) By Treatment: Chemotherapy, Radiotherapy, Surgery, Other Treatments

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Oncology Centers, Ambulatory Surgery Centers

Subsegments:

1) By Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Pancreatic Neuroendocrine Tumors (pNETs), Small Intestinal Neuroendocrine Tumors, Gastric Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors

2) By Carcinoid Tumors: Pulmonary Carcinoid Tumors, Gastrointestinal Carcinoid Tumors

3) By Pheochromocytoma: Adrenal Pheochromocytoma, Extra-Adrenal Paraganglioma

4) By Medullary Thyroid Carcinoma: Sporadic Medullary Thyroid Carcinoma, Hereditary Medullary Thyroid Carcinoma (MEN2-Associated)

Neuroendocrine Carcinoma Market Size and growth rate 2025 to 2029: Graph

What Is The Neuroendocrine Carcinoma Market Size 2025 And Growth Rate?

The neuroendocrine carcinoma market size has grown strongly in recent years. It will grow from $1.63 billion in 2024 to $1.76 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to the rise of the imaging sector, an increase in the incidence of neuroendocrine tumors, increasing investments, increasing government initiatives, and demand for treatments for neuroendocrine tumors.

What Is The Neuroendocrine Carcinoma Market Growth Forecast?

The neuroendocrine carcinoma market size is expected to see strong growth in the next few years. It will grow to $2.33 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to the increasing incidence rate of cancer disease, increasing rate of product approval, rising usage of improved diagnostic imaging methods, growth of targeted therapies, and increasing rate of diagnosis and treatment options available. Major trends in the forecast period include the advancement in diagnostic technologies, enhanced imaging technologies, targeted treatment approaches, advancements in neuroendocrine tumor management, and the advancement in targeted therapies and immunotherapies.

Book your 30 minutes free consultation with our research experts

Contact Us

What Is Driving The Neuroendocrine Carcinoma Market: Growth Of Targeted Therapies Driving The Market Expansion

The growth of targeted therapies is expected to propel the growth of the neuroendocrine carcinoma market going forward. Targeted therapies are treatments designed to precisely address and disrupt the molecular processes or genetic alterations that cause a disease, especially cancer. The demand for targeted therapies rises due to factors such as their precision in treating specific genetic mutations, advancements in personalized medicine, and better patient outcomes with fewer side effects. Neuroendocrine carcinoma enables the development of targeted therapies that specifically address the tumor’s genetic and biochemical profiles, enhancing treatment precision and effectiveness. For instance, in July 2023, according to the report published by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, at the end of Q1 2023, there were 247 gene therapies in Phase II, but this number rose by 5% to reach 260 by the end of Q2. Therefore, the growth of targeted therapies is driving the growth of the neuroendocrine carcinoma market.

Who Are The Major Players In The Global Neuroendocrine Carcinoma Market?

Major companies operating in the neuroendocrine carcinoma market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Exelixis Inc., Lantheus Holdings Inc., HUTCHMED Limited, Dana-Farber Cancer Institute Inc., Abdera Therapeutics Inc., Orano Med S.A, Eckert & Ziegler Radiopharma GmbH, Callisto Pharmaceuticals Inc., RadioMedix Inc., Clarity Pharmaceuticals Limited, Delcath Systems Inc., Provectus Biopharmaceuticals Inc.

What Are The Key Trends Of The Global Neuroendocrine Carcinoma Market: Advancements In Targeted Radiopharmaceutical Therapy For Neuroendocrine Carcinoma Treatment

Major companies operating in the neuroendocrine carcinoma market are focusing on developing advanced therapies, such as targeted radiopharmaceutical therapy, to improve treatment precision and patient outcomes. Targeted radiopharmaceutical therapy involves using radioactive molecules that specifically target and deliver radiation to cancer cells, minimizing harm to healthy tissue. For instance, in September 2024, Abdera Therapeutics Inc., a Canada-based biotechnology company, received the Food and Drug Administration (FDA)-granted orphan drug designation for ABD-147 for the treatment of neuroendocrine carcinoma. It is designed to selectively target tumors expressing the DLL3 protein, commonly upregulated in aggressive neuroendocrine cancers such as small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). This designation offers significant development advantages, including tax credits for clinical trials and the potential for market exclusivity, positioning ABD-147 as a promising treatment in this specialized oncology space.

What Are Latest Mergers And Acquisitions In The Neuroendocrine Carcinoma Market: Bristol-Myers Squibb Acquired RayzeBio To Enhance Oncology Pipeline With Targeted Radiopharmaceuticals

In February 2024, Bristol-Myers Squibb Company, a US-based pharmaceutical company, acquired RayzeBio, Inc. for $4.1 billion. With this acquisition, Bristol-Myers Squibb aims to strengthen its oncology pipeline, particularly in the treatment of neuroendocrine tumors and other hard-to-treat cancers, by leveraging RayzeBio's expertise in targeted therapies and innovative drug development. RayzeBio Inc. is a US-based company that provides treatment for gastroenteropancreatic neuroendocrine tumors.

What Is The Regional Outlook For The Global Neuroendocrine Carcinoma Market?

North America was the largest region in the neuroendocrine carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroendocrine carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neuroendocrine carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neuroendocrine Carcinoma  Market?

The neuroendocrine carcinoma market consists of revenues earned by entities by providing services such as hormonal symptom management, long-term care plans, pain management, immunotherapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuroendocrine carcinoma market also consists of sales of products including somatostatin analogs, positron emission tomography (PET) scanners, needles and equipment, infusion pumps, and drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Neuroendocrine Carcinoma  Industry?

The neuroendocrine carcinoma market research report is one of a series of new reports from The Business Research Company that provides neuroendocrine carcinoma market statistics, including the neuroendocrine carcinoma industry global market size, regional shares, competitors with the neuroendocrine carcinoma market share, detailed neuroendocrine carcinoma market segments, market trends, and opportunities, and any further data you may need to thrive in the neuroendocrine carcinoma industry. This neuroendocrine carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Neuroendocrine Carcinoma Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 $1.76 billion
Revenue Forecast In 2034 $2.33 billion
Growth Rate CAGR of 7.3% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The neuroendocrine carcinoma market covered in this report is segmented –
1) By Type: Gastroenteropancreatic Neuroendocrine Tumors, Carcinoid Tumors, Pheochromocytoma, Medullary Thyroid Carcinoma
2) By Diagnostic Tools: Imaging, Biopsy, Serology
3) By Treatment: Chemotherapy, Radiotherapy, Surgery, Other Treatments
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Oncology Centers, Ambulatory Surgery Centers Subsegments:
1) By Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Pancreatic Neuroendocrine Tumors (pNETs), Small Intestinal Neuroendocrine Tumors, Gastric Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors
2) By Carcinoid Tumors: Pulmonary Carcinoid Tumors, Gastrointestinal Carcinoid Tumors
3) By Pheochromocytoma: Adrenal Pheochromocytoma, Extra-Adrenal Paraganglioma
4) By Medullary Thyroid Carcinoma: Sporadic Medullary Thyroid Carcinoma, Hereditary Medullary Thyroid Carcinoma (MEN2-Associated)
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Exelixis Inc., Lantheus Holdings Inc., HUTCHMED Limited, Dana-Farber Cancer Institute Inc., Abdera Therapeutics Inc., Orano Med S.A, Eckert & Ziegler Radiopharma GmbH, Callisto Pharmaceuticals Inc., RadioMedix Inc., Clarity Pharmaceuticals Limited, Delcath Systems Inc., Provectus Biopharmaceuticals Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Neuroendocrine Carcinoma Market Characteristics

    3. Neuroendocrine Carcinoma Market Trends And Strategies

    4. Neuroendocrine Carcinoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

    5. Global Neuroendocrine Carcinoma Growth Analysis And Strategic Analysis Framework

    5.1. Global Neuroendocrine Carcinoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Neuroendocrine Carcinoma Market Growth Rate Analysis

    5.4. Global Neuroendocrine Carcinoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Neuroendocrine Carcinoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Neuroendocrine Carcinoma Total Addressable Market (TAM)

    6. Neuroendocrine Carcinoma Market Segmentation

    6.1. Global Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Gastroenteropancreatic Neuroendocrine Tumors

    Carcinoid Tumors

    Pheochromocytoma

    Medullary Thyroid Carcinoma

    6.2. Global Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Imaging

    Biopsy

    Serology

    6.3. Global Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Chemotherapy

    Radiotherapy

    Surgery

    Other Treatments

    6.4. Global Neuroendocrine Carcinoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospital Pharmacies

    Retail Pharmacies

    Online Pharmacies

    6.5. Global Neuroendocrine Carcinoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospitals

    Clinics

    Oncology Centers

    Ambulatory Surgery Centers

    6.6. Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Pancreatic Neuroendocrine Tumors (pNETs)

    Small Intestinal Neuroendocrine Tumors

    Gastric Neuroendocrine Tumors

    Colorectal Neuroendocrine Tumors

    6.7. Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Carcinoid Tumors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Pulmonary Carcinoid Tumors

    Gastrointestinal Carcinoid Tumors

    6.8. Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Pheochromocytoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Adrenal Pheochromocytoma

    Extra-Adrenal Paraganglioma

    6.9. Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Medullary Thyroid Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Sporadic Medullary Thyroid Carcinoma

    Hereditary Medullary Thyroid Carcinoma (MEN2-Associated)

    7. Neuroendocrine Carcinoma Market Regional And Country Analysis

    7.1. Global Neuroendocrine Carcinoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Neuroendocrine Carcinoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Neuroendocrine Carcinoma Market

    8.1. Asia-Pacific Neuroendocrine Carcinoma Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Neuroendocrine Carcinoma Market

    9.1. China Neuroendocrine Carcinoma Market Overview

    9.2. China Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Neuroendocrine Carcinoma Market

    10.1. India Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Neuroendocrine Carcinoma Market

    11.1. Japan Neuroendocrine Carcinoma Market Overview

    11.2. Japan Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Neuroendocrine Carcinoma Market

    12.1. Australia Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Neuroendocrine Carcinoma Market

    13.1. Indonesia Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Neuroendocrine Carcinoma Market

    14.1. South Korea Neuroendocrine Carcinoma Market Overview

    14.2. South Korea Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Neuroendocrine Carcinoma Market

    15.1. Western Europe Neuroendocrine Carcinoma Market Overview

    15.2. Western Europe Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Neuroendocrine Carcinoma Market

    16.1. UK Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Neuroendocrine Carcinoma Market

    17.1. Germany Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Neuroendocrine Carcinoma Market

    18.1. France Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Neuroendocrine Carcinoma Market

    19.1. Italy Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Neuroendocrine Carcinoma Market

    20.1. Spain Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Neuroendocrine Carcinoma Market

    21.1. Eastern Europe Neuroendocrine Carcinoma Market Overview

    21.2. Eastern Europe Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Neuroendocrine Carcinoma Market

    22.1. Russia Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Neuroendocrine Carcinoma Market

    23.1. North America Neuroendocrine Carcinoma Market Overview

    23.2. North America Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Neuroendocrine Carcinoma Market

    24.1. USA Neuroendocrine Carcinoma Market Overview

    24.2. USA Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Neuroendocrine Carcinoma Market

    25.1. Canada Neuroendocrine Carcinoma Market Overview

    25.2. Canada Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Neuroendocrine Carcinoma Market

    26.1. South America Neuroendocrine Carcinoma Market Overview

    26.2. South America Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Neuroendocrine Carcinoma Market

    27.1. Brazil Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Neuroendocrine Carcinoma Market

    28.1. Middle East Neuroendocrine Carcinoma Market Overview

    28.2. Middle East Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Neuroendocrine Carcinoma Market

    29.1. Africa Neuroendocrine Carcinoma Market Overview

    29.2. Africa Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Neuroendocrine Carcinoma Market Competitive Landscape And Company Profiles

    30.1. Neuroendocrine Carcinoma Market Competitive Landscape

    30.2. Neuroendocrine Carcinoma Market Company Profiles

    30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

    31. Neuroendocrine Carcinoma Market Other Major And Innovative Companies

    31.1. Novartis AG

    31.2. Amgen Inc.

    31.3. Boehringer Ingelheim GmbH

    31.4. Exelixis Inc.

    31.5. Lantheus Holdings Inc.

    31.6. HUTCHMED Limited

    31.7. Dana-Farber Cancer Institute Inc.

    31.8. Abdera Therapeutics Inc.

    31.9. Orano Med S.A

    31.10. Eckert & Ziegler Radiopharma GmbH

    31.11. Callisto Pharmaceuticals Inc.

    31.12. RadioMedix Inc.

    31.13. Clarity Pharmaceuticals Limited

    31.14. Delcath Systems Inc.

    31.15. Provectus Biopharmaceuticals Inc.

    32. Global Neuroendocrine Carcinoma Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Neuroendocrine Carcinoma Market

    34. Recent Developments In The Neuroendocrine Carcinoma Market

    35. Neuroendocrine Carcinoma Market High Potential Countries, Segments and Strategies

    35.1 Neuroendocrine Carcinoma Market In 2029 - Countries Offering Most New Opportunities

    35.2 Neuroendocrine Carcinoma Market In 2029 - Segments Offering Most New Opportunities

    35.3 Neuroendocrine Carcinoma Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Neuroendocrine Carcinoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Neuroendocrine Carcinoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Carcinoid Tumors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Pheochromocytoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Medullary Thyroid Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Neuroendocrine Carcinoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Neuroendocrine Carcinoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Asia-Pacific, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: China, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: India, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Japan, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Australia, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Indonesia, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: South Korea, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Western Europe, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: UK, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Germany, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: France, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Italy, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Spain, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Eastern Europe, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Russia, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: North America, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: USA, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Canada, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: South America, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Brazil, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Middle East, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Africa, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Pfizer Inc. Financial Performance
  • Table 81: Merck & Co. Inc. Financial Performance
  • Table 82: AbbVie Inc. Financial Performance
  • Table 83: Bristol-Myers Squibb Company Financial Performance
  • Table 84: AstraZeneca plc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Neuroendocrine Carcinoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Neuroendocrine Carcinoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Carcinoid Tumors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Pheochromocytoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Medullary Thyroid Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Neuroendocrine Carcinoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Neuroendocrine Carcinoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Asia-Pacific, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: China, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: India, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Japan, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Australia, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Indonesia, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: South Korea, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Western Europe, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: UK, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Germany, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: France, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Italy, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Spain, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Eastern Europe, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Russia, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: North America, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: USA, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Canada, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: South America, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Brazil, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Middle East, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Africa, Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Pfizer Inc. Financial Performance
  • Figure 81: Merck & Co. Inc. Financial Performance
  • Figure 82: AbbVie Inc. Financial Performance
  • Figure 83: Bristol-Myers Squibb Company Financial Performance
  • Figure 84: AstraZeneca plc Financial Performance

Global Healthcare Automation Market 2022 – Market Opportunities And Strategies

Read More

Global Central Lab Market 2022 – Market Opportunities And Strategies

Read More

What Is The Biohacking Market Overview In 2022?

Read More

How Will The Healthcare Claims Management Solutions Market Grow In 2022?

Read More

The Business Research Company offers the medical aesthetics market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the clinical chemistry market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the medical tourism market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the clinical chemistry market market research report 2022 with industry size, share, segments and market growth

Read More

Neuroendocrine Tumor Treatment Global Market Report 2025 – By Product (Somatostatin Analogs (SSAs), Targeted Therapy, Chemotherapy, Others Products), By Indication (Lungs, Pancreas, Gastrointestinal, Others Indications), By End-Users (Hospitals, Oncology Centers, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Hepatocellular Carcinoma Drugs Global Market Report 2025 – By Type (Brachytherapy, Chemotherapy), By Drug Class (PD-1/PD-L1 Inhibitors, Tyrosine Kinase Inhibitors), By End User (Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Unresectable Hepatocellular Carcinoma Global Market Report 2025 – By Type (Primary, Secondary, Benign Liver Growth), By Treatment Type (Chemotherapy, Molecularly Targeted Therapy, Immunotherapy, Other Treatments), By End-Users (Hospitals, Specialty Clinics, Cancer Centers) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Merkel Cell Carcinoma Treatment Global Market Report 2025 – By Diagnosis (Physical Examination, Sentinel Node Biopsy, Imaging Test), By Therapy (Surgical Excision, Micrographic Surgery, Radiation, Chemotherapy, Other Therapies), By Route Of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By End User (Hospitals, Homecare, Specialty Centers, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Basal Cell Carcinoma Treatment Global Market Report 2025 – By Treatment (Surgery, Medication, Other Treatments), By Route Of Administration (Oral, Parenteral, Other Route Of Administrations), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By End-User (Hospitals, Specialty Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Urothelial Carcinoma Treatment Global Market Report 2025 – By Type (Non-Invasive Urothelial Carcinoma Treatment, Invasive Urothelial Carcinoma Treatment), By Treatment (Immunotherapy, Radiotherapy, Chemotherapy), By Cancer Type (Bladder Cancer, Urethral Cancer, Ureteric And Renal Pelvic Cancer), By End-Users (Hospitals, Homecare, Specialty Centers, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Nasopharyngeal Carcinoma Treatment Global Market Report 2025 – By Types (Non-Keratinizing Undifferentiated Carcinoma, Non-Keratinizing Differentiated Carcinoma, Keratinizing Squamous Cell Carcinoma), By Drug (Ellence, Taxotere, Bleomycin, Methotrexate), By Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, Other Therapies), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Respiratory Disease Testing Global Market Report 2025 – By Test Type (Imaging Tests, Mechanical Tests, In-Vitro Diagnostic Tests), By Products (Lung Volume, Imaging, Spirometry, Peak Flow, Blood Gas, Other Products), By Application (Chronic Obstructive Pulmonary Disease, Lung Cancer, Asthma, Tuberculosis Female, Other Application), By End-User (Hospitals, Physician clinics, Clinical laboratories, Other End-User) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Neuroendocrine Carcinoma market?

Neuroendocrine carcinoma (NEC) refers to a rare and aggressive type of cancer that originates in neuroendocrine cells, which have traits of both nerve cells and hormone-producing cells. They are used for identifying and treating tumors that can develop in various organs, including the lungs, pancreas, and gastrointestinal tract, often requiring a combination of surgery, chemotherapy, and targeted therapies. For further insights on the Neuroendocrine Carcinoma market, request a sample here

How will the Neuroendocrine Carcinoma market drivers and restraints affect the market dynamics? What forces will shape the Neuroendocrine Carcinoma industry going forward?

The Neuroendocrine Carcinoma market major growth driver - Growth Of Targeted Therapies Driving The Market Expansion. For further insights on the Neuroendocrine Carcinoma market, request a sample here

What is the forecast market size or the forecast market value of the Neuroendocrine Carcinoma market?

The Neuroendocrine Carcinoma market size has grown strongly in recent years. The neuroendocrine carcinoma market size has grown strongly in recent years. It will grow from $1.63 billion in 2024 to $1.76 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to the rise of the imaging sector, an increase in the incidence of neuroendocrine tumors, increasing investments, increasing government initiatives, and demand for treatments for neuroendocrine tumors. The neuroendocrine carcinoma market size is expected to see strong growth in the next few years. It will grow to $2.33 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to the increasing incidence rate of cancer disease, increasing rate of product approval, rising usage of improved diagnostic imaging methods, growth of targeted therapies, and increasing rate of diagnosis and treatment options available. Major trends in the forecast period include the advancement in diagnostic technologies, enhanced imaging technologies, targeted treatment approaches, advancements in neuroendocrine tumor management, and the advancement in targeted therapies and immunotherapies. For further insights on the Neuroendocrine Carcinoma market, request a sample here

How is the Neuroendocrine Carcinoma market segmented?

The neuroendocrine carcinoma market covered in this report is segmented –
1) By Type: Gastroenteropancreatic Neuroendocrine Tumors, Carcinoid Tumors, Pheochromocytoma, Medullary Thyroid Carcinoma
2) By Diagnostic Tools: Imaging, Biopsy, Serology
3) By Treatment: Chemotherapy, Radiotherapy, Surgery, Other Treatments
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Oncology Centers, Ambulatory Surgery Centers

Subsegments:
1) By Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Pancreatic Neuroendocrine Tumors (pNETs), Small Intestinal Neuroendocrine Tumors, Gastric Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors
2) By Carcinoid Tumors: Pulmonary Carcinoid Tumors, Gastrointestinal Carcinoid Tumors
3) By Pheochromocytoma: Adrenal Pheochromocytoma, Extra-Adrenal Paraganglioma
4) By Medullary Thyroid Carcinoma: Sporadic Medullary Thyroid Carcinoma, Hereditary Medullary Thyroid Carcinoma (MEN2-Associated) For further insights on the Neuroendocrine Carcinoma market, request a sample here

Which region has the largest share of the Neuroendocrine Carcinoma market? What are the other regions covered in the report?

North America was the largest region in the neuroendocrine carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroendocrine carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Neuroendocrine Carcinoma market, request a sample here.

Who are the major players in the Neuroendocrine Carcinoma market?

Major companies operating in the neuroendocrine carcinoma market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Exelixis Inc., Lantheus Holdings Inc., HUTCHMED Limited, Dana-Farber Cancer Institute Inc., Abdera Therapeutics Inc., Orano Med S.A, Eckert & Ziegler Radiopharma GmbH, Callisto Pharmaceuticals Inc., RadioMedix Inc., Clarity Pharmaceuticals Limited, Delcath Systems Inc., Provectus Biopharmaceuticals Inc. . For further insights on the Neuroendocrine Carcinoma market, request a sample here.

What are the key trends in the Neuroendocrine Carcinoma market?

Major trends in the Neuroendocrine Carcinoma market include Advancements In Targeted Radiopharmaceutical Therapy For Neuroendocrine Carcinoma Treatment. For further insights on the Neuroendocrine Carcinoma market, request a sample here.

What are the major opportunities in the Neuroendocrine Carcinoma market? What are the strategies for the Neuroendocrine Carcinoma market?

For detailed insights on the major opportunities and strategies in the Neuroendocrine Carcinoma market, request a sample here.

How does the Neuroendocrine Carcinoma market relate to the overall economy and other similar markets?

For detailed insights on the key dynamics influencing the Neuroendocrine Carcinoma market growth and SWOT analysis of the Neuroendocrine Carcinoma industry, request a sample here.

For detailed insights on Neuroendocrine Carcinoma's relation to the overall economy and other similar markets,

What are the latest mergers and acquisitions in the Neuroendocrine Carcinoma industry? request a sample here.

For detailed insights on the mergers and acquisitions in the Neuroendocrine Carcinoma industry,

What are the key dynamics influencing the Neuroendocrine Carcinoma market growth? SWOT analysis of the Neuroendocrine Carcinoma market. request a sample here.